CatalystFDA/Bio

Syndax plummets as IPF asset axatilimab fails in phase 2 trial

Axatilimab's phase 2 failure in IPF drives Syndax shares sharply lower.

What changed

Axatilimab's phase 2 failure in IPF drives Syndax shares sharply lower.

Why it matters

Axatilimab's phase 2 failure in IPF drives Syndax shares sharply lower. — impact context not separately stored; see What changed.

Sources